Cargando…
Acquired Hemophilia A Successfully Treated with Rituximab
Acquired hemophilia A (AHA) is a rare bleeding disorder due to the development of specific autoantibodies against factor VIII. The anti-CD20 monoclonal antibody Rituximab has been proven to be effective in obtaining a long-term suppression of inhibitors of AHA, besides other immunosuppressive standa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344169/ https://www.ncbi.nlm.nih.gov/pubmed/25745551 http://dx.doi.org/10.4084/MJHID.2015.024 |
_version_ | 1782359371463786496 |
---|---|
author | D’Arena, Giovanni Grandone, Elvira Di Minno, Matteo Nicola Dario Musto, Pellegrino Di Minno, Giovanni |
author_facet | D’Arena, Giovanni Grandone, Elvira Di Minno, Matteo Nicola Dario Musto, Pellegrino Di Minno, Giovanni |
author_sort | D’Arena, Giovanni |
collection | PubMed |
description | Acquired hemophilia A (AHA) is a rare bleeding disorder due to the development of specific autoantibodies against factor VIII. The anti-CD20 monoclonal antibody Rituximab has been proven to be effective in obtaining a long-term suppression of inhibitors of AHA, besides other immunosuppressive standard treatments. Here we describe a case of idiopathic AHA in a 60-year old man successfully treated with rituximab. He showed a complete clinical response with a normalization of clotting parameters after 5 weekly courses of rituximab given at a dose of 375 mg/sqm., but after stopping rituximab, an initial worsening of coagulation parameters induced the addition of 3 further courses. At present, the patient is in complete clinical and hematological remission after 200 days. This case confirms that Rituximab may be a safe and useful tool to treat AHA and, a prolonged administration can overcome the initial resistance. However, the precise position of this drug in the therapeutic strategy (first or second-line, alone or in combination with other drugs) remains to be established and warrants further investigation. |
format | Online Article Text |
id | pubmed-4344169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Università Cattolica del Sacro Cuore |
record_format | MEDLINE/PubMed |
spelling | pubmed-43441692015-03-05 Acquired Hemophilia A Successfully Treated with Rituximab D’Arena, Giovanni Grandone, Elvira Di Minno, Matteo Nicola Dario Musto, Pellegrino Di Minno, Giovanni Mediterr J Hematol Infect Dis Case Report Acquired hemophilia A (AHA) is a rare bleeding disorder due to the development of specific autoantibodies against factor VIII. The anti-CD20 monoclonal antibody Rituximab has been proven to be effective in obtaining a long-term suppression of inhibitors of AHA, besides other immunosuppressive standard treatments. Here we describe a case of idiopathic AHA in a 60-year old man successfully treated with rituximab. He showed a complete clinical response with a normalization of clotting parameters after 5 weekly courses of rituximab given at a dose of 375 mg/sqm., but after stopping rituximab, an initial worsening of coagulation parameters induced the addition of 3 further courses. At present, the patient is in complete clinical and hematological remission after 200 days. This case confirms that Rituximab may be a safe and useful tool to treat AHA and, a prolonged administration can overcome the initial resistance. However, the precise position of this drug in the therapeutic strategy (first or second-line, alone or in combination with other drugs) remains to be established and warrants further investigation. Università Cattolica del Sacro Cuore 2015-03-01 /pmc/articles/PMC4344169/ /pubmed/25745551 http://dx.doi.org/10.4084/MJHID.2015.024 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report D’Arena, Giovanni Grandone, Elvira Di Minno, Matteo Nicola Dario Musto, Pellegrino Di Minno, Giovanni Acquired Hemophilia A Successfully Treated with Rituximab |
title | Acquired Hemophilia A Successfully Treated with Rituximab |
title_full | Acquired Hemophilia A Successfully Treated with Rituximab |
title_fullStr | Acquired Hemophilia A Successfully Treated with Rituximab |
title_full_unstemmed | Acquired Hemophilia A Successfully Treated with Rituximab |
title_short | Acquired Hemophilia A Successfully Treated with Rituximab |
title_sort | acquired hemophilia a successfully treated with rituximab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344169/ https://www.ncbi.nlm.nih.gov/pubmed/25745551 http://dx.doi.org/10.4084/MJHID.2015.024 |
work_keys_str_mv | AT darenagiovanni acquiredhemophiliaasuccessfullytreatedwithrituximab AT grandoneelvira acquiredhemophiliaasuccessfullytreatedwithrituximab AT diminnomatteonicoladario acquiredhemophiliaasuccessfullytreatedwithrituximab AT mustopellegrino acquiredhemophiliaasuccessfullytreatedwithrituximab AT diminnogiovanni acquiredhemophiliaasuccessfullytreatedwithrituximab |